ArticleHaematologica2019
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Cardiovascular Care in Multiple Myeloma: A Comprehensive Review and Integrated Systems-Based Approach from a UK Cardio-Oncology Centre of Excellence.Current cardiology reports · 2026Review
- Article
- Patient-reported outcomes - the missing link to advancing light chain (AL) amyloidosis clinical research.Blood reviews · 2025Review
- Incidence and prevalence of light chain amyloidosis in the United States in 2019-2021 using Optum EHR data.Scientific reports · 2025Article
- Atrial cardiomyopathy in cardiac amyloidosis: clinical imaging and manifestations.NPJ cardiovascular health · 2025Article
- Enhancing prognostic guidance in renal light-chain amyloidosis: a new staging system incorporating pathological characters.International urology and nephrology · 2025Article
- Amyloidosis in Childhood: A Review of Clinical Features and Comparison with Adult Forms.Journal of clinical medicine · 2024Review
- Advancing precision medicine in immunoglobulin light-chain amyloidosis: a novel prognostic model incorporating multi-organ indicators.Internal and emergency medicine · 2024Article
- Article
- Clinical characteristics and prognosis of a Chinese cohort with systemic light chain amyloidosis: a single-center study.International journal of hematology · 2023Article
- 2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis.Acta Cardiologica Sinica · 2023Article
- Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist.Internal and emergency medicine · 2022Review
- Clinical characteristics and prognostic value of renal immune complex deposition in patients with light chain amyloidosis.Frontiers in oncology · 2022Article
- Biomarkers in AL Amyloidosis.International journal of molecular sciences · 2021Review
- Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.Orphanet journal of rare diseases · 2021Article
- Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).Clinical research in cardiology : official journal of the German Cardiac Society · 2021Review
- Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation.Bone marrow transplantation · 2021Article
- Review
- Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.Haematologica · 2020Article
- Amyloidosis in Heart Failure.Current heart failure reports · 2019Review
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic light chain amyloidosis is a rare and life-threatening disorder, for which accurate risk stratification is crucial. Current cardiac staging systems (MAYO2004, MAYO3b, and MAYO2012) are mainly based on biomarkers, which have uncertain reliability in the context of atrial fibrillation, arrhythmia or pacemaker stimulation as well as renal insufficiency. We compared the performance of the established staging systems with particular regard to these comorbidities in 1,224 patients with systemic light chain amyloidosis diagnosed at our center from July 2002 until March 2017. We first characterized the subsets with an estimated glomerular filtration rate <50 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.